Evaluation of tamoxifen as a therapy to augment alpha-1-antitrypsin concentrations in Z homozygous alpha-1-antitrypsin-deficient subjects

M. D. Wewers, M. L. Brantly, M. A. Casolaro, Ronald Crystal

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Tamoxifen, an agent that binds to intracytoplasmic estrogen receptors, was evaluated as a possible means of increasing alpha-1-antitrypsin (α1AT) synthesis and/or secretion and thus α1AT serum levels in subjects with the homozygous form of α1AT deficiency. Administration of tamoxifen (10 mg twice daily) to 30 Z homozygotes for a 30-day period was not associated with adverse reactions. However, although serum α1AT levels increased significantly (p < 0.03), the increase was minor (average pretreatment levels, 32 ± 1 mg/dl; levels at 30 days of therapy, 35 ± 1 mg/dl) and far below the 'threshold' level of 80 mg/dl considered 'protective' against an increased risk for emphysema. Thus, while the concept that increasing α1AT synthesis and/or secretion is a rational goal for treating the Z homozygous form of α1AT deficiency, tamoxifen will not be useful in this regard.

Original languageEnglish
Pages (from-to)401-402
Number of pages2
JournalAmerican Review of Respiratory Disease
Volume135
Issue number2
Publication statusPublished - 1 Jan 1987
Externally publishedYes

Fingerprint

alpha 1-Antitrypsin
Tamoxifen
Emphysema
Homozygote
Serum
Estrogen Receptors
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Evaluation of tamoxifen as a therapy to augment alpha-1-antitrypsin concentrations in Z homozygous alpha-1-antitrypsin-deficient subjects. / Wewers, M. D.; Brantly, M. L.; Casolaro, M. A.; Crystal, Ronald.

In: American Review of Respiratory Disease, Vol. 135, No. 2, 01.01.1987, p. 401-402.

Research output: Contribution to journalArticle

@article{5f08d6153b85442d9814521b1af36c98,
title = "Evaluation of tamoxifen as a therapy to augment alpha-1-antitrypsin concentrations in Z homozygous alpha-1-antitrypsin-deficient subjects",
abstract = "Tamoxifen, an agent that binds to intracytoplasmic estrogen receptors, was evaluated as a possible means of increasing alpha-1-antitrypsin (α1AT) synthesis and/or secretion and thus α1AT serum levels in subjects with the homozygous form of α1AT deficiency. Administration of tamoxifen (10 mg twice daily) to 30 Z homozygotes for a 30-day period was not associated with adverse reactions. However, although serum α1AT levels increased significantly (p < 0.03), the increase was minor (average pretreatment levels, 32 ± 1 mg/dl; levels at 30 days of therapy, 35 ± 1 mg/dl) and far below the 'threshold' level of 80 mg/dl considered 'protective' against an increased risk for emphysema. Thus, while the concept that increasing α1AT synthesis and/or secretion is a rational goal for treating the Z homozygous form of α1AT deficiency, tamoxifen will not be useful in this regard.",
author = "Wewers, {M. D.} and Brantly, {M. L.} and Casolaro, {M. A.} and Ronald Crystal",
year = "1987",
month = "1",
day = "1",
language = "English",
volume = "135",
pages = "401--402",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "2",

}

TY - JOUR

T1 - Evaluation of tamoxifen as a therapy to augment alpha-1-antitrypsin concentrations in Z homozygous alpha-1-antitrypsin-deficient subjects

AU - Wewers, M. D.

AU - Brantly, M. L.

AU - Casolaro, M. A.

AU - Crystal, Ronald

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Tamoxifen, an agent that binds to intracytoplasmic estrogen receptors, was evaluated as a possible means of increasing alpha-1-antitrypsin (α1AT) synthesis and/or secretion and thus α1AT serum levels in subjects with the homozygous form of α1AT deficiency. Administration of tamoxifen (10 mg twice daily) to 30 Z homozygotes for a 30-day period was not associated with adverse reactions. However, although serum α1AT levels increased significantly (p < 0.03), the increase was minor (average pretreatment levels, 32 ± 1 mg/dl; levels at 30 days of therapy, 35 ± 1 mg/dl) and far below the 'threshold' level of 80 mg/dl considered 'protective' against an increased risk for emphysema. Thus, while the concept that increasing α1AT synthesis and/or secretion is a rational goal for treating the Z homozygous form of α1AT deficiency, tamoxifen will not be useful in this regard.

AB - Tamoxifen, an agent that binds to intracytoplasmic estrogen receptors, was evaluated as a possible means of increasing alpha-1-antitrypsin (α1AT) synthesis and/or secretion and thus α1AT serum levels in subjects with the homozygous form of α1AT deficiency. Administration of tamoxifen (10 mg twice daily) to 30 Z homozygotes for a 30-day period was not associated with adverse reactions. However, although serum α1AT levels increased significantly (p < 0.03), the increase was minor (average pretreatment levels, 32 ± 1 mg/dl; levels at 30 days of therapy, 35 ± 1 mg/dl) and far below the 'threshold' level of 80 mg/dl considered 'protective' against an increased risk for emphysema. Thus, while the concept that increasing α1AT synthesis and/or secretion is a rational goal for treating the Z homozygous form of α1AT deficiency, tamoxifen will not be useful in this regard.

UR - http://www.scopus.com/inward/record.url?scp=0023128087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023128087&partnerID=8YFLogxK

M3 - Article

C2 - 3492949

AN - SCOPUS:0023128087

VL - 135

SP - 401

EP - 402

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 2

ER -